Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics develops oncology biologics built on its PROBODY therapeutic platform, which masks and conditionally activates antibody-based therapies in the tumor microenvironment. News about CTMX commonly covers clinical updates for varsetatug masetecan, or Varseta-M, an EpCAM PROBODY ADC studied in advanced colorectal cancer and other EpCAM-expressing tumors, as well as CX-801, a masked Interferon-alpha-2b program initially developed in advanced melanoma.
Company updates also address financial results, research and development spending, cash runway, equity financings, and collaboration activity with Amgen, Regeneron, and Moderna. Recurring pipeline coverage includes dose-expansion data, combination-study activity, regulatory interactions, and PROBODY platform applications such as bispecific immunotherapies and T-cell engagers.
CytomX Therapeutics (CTMX) announced key details regarding oral and poster presentations for its clinical-stage portfolio at the ASCO20 Virtual Scientific Program scheduled from May 29-31, 2020. Presentations for CX-072, CX-2009, and CX-2029 will provide pivotal clinical data, including initial results for CX-2029, a Probody Drug Conjugate targeting CD71. The data cutoff dates for these presentations are five months later than previously set. The company emphasizes the potential of its Probody platform to offer more effective cancer therapies.
CytomX Therapeutics (CTMX) reported its Q1 2020 financial results, highlighting a revenue increase to $49.6 million from $29.5 million in Q1 2019, primarily due to milestone payments from AbbVie and Bristol Myers Squibb. Cash reserves decreased to $247.9 million. The company paused new patient enrollment in its CX-2009 study due to COVID-19 but is focusing on undruggable targets through key collaborations, including an $80 million agreement with Astellas. Despite challenges from the pandemic, CytomX remains poised for future growth with ongoing clinical trials and strategic partnerships.
Summary not available.